Evidence presented at a major American conference suggests that the extent of virological suppression achievable with long-acting injectable antiviral products appears to be similr to that attained using daily oral treatment with highly active antiretroviral treatments. Although more research is needed, these results point to the promise of this approach. Conference coverage is available to read here